In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

GSK gets rights to Prosensa's PRO051, options on other molecules; terminated

Executive Summary

Prosensa BV (antisense oligonucleotides that modify disease-causing genes) has licensed GlaxoSmithKline exclusive global rights to its lead candidate Phase I/II PRO051 for Duchenne muscular dystrophy (DMD), plus exclusive options on Phase I PRO044 and two other molecules once studies are completed. Each of these four therapeutics is for a different subpopulation of DMD. The alliance was established under GSK's Center of Excellence for External Drug Discovery (CEEDD).
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Co-Promotion
    • Includes Contract
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)

Related Companies